Looking up the ticker with the regulator···
0s · usually 20–30 seconds for a cold read
Looking up the ticker with the regulator···
0s · usually 20–30 seconds for a cold read
Pfizer Inc.
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice.
Weak signals across every dimension
Get notified when we ship meaningful updates. No spam, no daily noise.
Data: SEC EDGAR filings · prices Marketstack · estimates Finnhub · updated 10 Jul 2026, 23:46 UTC
1 of 5 met · composite in line with peers
Business quality, valuation against the sector, and position in the 52-week range — whether they line up or not.
Mixed signals
Profitability
3/4
Debt & liquidity
0/3
Efficiency
2/2
Profitability is under strain. The F-Score of 5/9 reflects mixed signals: cash generation remains solid, yet debt is climbing and the balance sheet shows stress. Debt/EBITDA sits at 5.3×, well above the sector median of 2.9×, which narrows the financial cushion. Revenue grew -1.6% year over year, trailing the sector median of 5.9% by -128%—growth is lagging. On valuation, the picture inverts. The P/E of 18.5× runs -33% below the sector median, and the P/B of 1.6× sits even cheaper at -74% below the median. Free cash flow yield reaches 6.9%, outpacing the sector by +72%. Consensus expects earnings growth ahead, and the company has beaten estimates in recent quarters. Yet the realized three-year EPS CAGR lags what analysts are pricing in—a gap worth watching. The composite score of 45/100 against a sector median reflects a business where low price masks weakening fundamentals rather than a hidden bargain.
| Ticker | Name | F-Score | ROE | Revenue YoY | Op. margin |
|---|---|---|---|---|---|
| ABBV | AbbVie | 8/9 | 15 367% |
Quarter-by-quarter classification · a retrospective read by the current logic · not a price forecast
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice. The method did not see these quarters in real time; this is the current logic applied to past reports.
The market prices in earnings growth; analyst sentiment is steady; has mostly beaten consensus.
Price against next year's expected earnings. The forward P/E already carries analyst optimism — read it alongside the “Versus consensus” line.
A forward P/E below the current one means the market expects earnings to grow; above it, to fall. The historical growth is realized figures from SEC filings, not a forecast.
The three-month change in the share of positive analyst ratings. This is sentiment, not an earnings-estimate revision, and not a call to act.
Pfizer's revenue growth sits 128% below the sector median at 5.86% year-over-year, while free cash flow yield runs 72% above median at 4.02%. At the August 4, 2026 report, track whether revenue acceleration appears and whether operating cash conversion remains strong enough to sustain that FCF yield advantage.
Debt-to-EBITDA stands 80% above the sector median at 2.93×, and the F-Score shows zero points on leverage and liquidity. Pull the most recent 10-K filing, focus on the debt schedule and management's discussion of refinancing plans, and assess whether leverage is trending down or stabilizing.
Pfizer trades at a P/E of 27.6× and P/B of 6.09×, both below sector medians. Pick two or three companies from the same-sector table and line up their P/E, P/B, and F-Score profitability components to see how Pfizer's valuation discount aligns with its quality gap relative to peers.
Steps you can check yourself, based on the figures in this brief.
Piotroski F-Score: nine binary tests of financial strength from the annual report. A ✓ marks a test passed, a dot (·) a test failed.
Over 4 years: -13%-82%+105%-8%
Over 4 years: 1.127.074.505.27
Over 4 years: +24%-41%+7%-2%
The context on the right shows how each figure compares with the sector median. The trend below tracks the change over recent fiscal years.
Beat consensus in 8 of 8 recent quarters — the company clears estimates regularly (consensus is often set conservatively).
Last quarter's EPS against consensus, plus the estimated date of the next report.
| +9% |
| 25% |
| ABT | Abbott | 6/9 | 13% | +6% | 18% |
| AMGN | Amgen | 7/9 | 106% | +10% | 25% |
| BMY | Bristol-Myers Squibb | 8/9 | 41% | -0% | — |
| CVS | CVS Health | 7/9 | 2% | +8% | 1% |
| DHR | Danaher | 5/9 | 7% | +3% | 19% |
| GILD | Gilead Sciences | 8/9 | 40% | +2% | 34% |
| ISRG | Intuitive Surgical | 6/9 | 17% | +21% | 29% |
| JNJ | Johnson & Johnson | 4/9 | 35% | +6% | — |
| LLY | Eli Lilly | 7/9 | 101% | +45% | — |
| MRK | Merck | 4/9 | 37% | +1% | — |
| PFE | Pfizer Inc. | 5/9 | 9% | -2% | — |
| TMO | Thermo Fisher | 5/9 | 13% | +4% | 17% |
| UNH | UnitedHealth | 7/9 | 18% | +12% | 4% |
A sample of 14 companies in the sector including the target, alphabetical, unranked. Data from the latest SEC annual reports.
Rule-based classification of fundamentals against the sector. Not a price forecast and not investment advice.
A simplified retrospective read: no analyst forecast (not available historically); the source is the annual report as of the date, so neighbouring quarters can rest on the same data. Quarters with the same classification in a row are merged into one row — each row is one change in the read, not a separate quarter. One ticker is an illustration of the classification logic, not statistics. How we calculate →
The last few quarters are recent context, not a fixed rate. Consensus for near quarters is set low, so companies clear it routinely; over long horizons the forecasts run the other way, too high.
A description of what the market and analysts expect. Not a price forecast and not investment advice. Analyst forecasts run systematically optimistic over long horizons — read them with that discount.